Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Potential cost-effectiveness of one-time screening for lung cancer (LC) ina high risk cohort
Autore:
Marshall, D; Simpson, KN; Earle, CC; Chu, CW;
Indirizzi:
Bayer Diagnost, Emeryville, CA USA Bayer Diagnost Emeryville CA USABayer Diagnost, Emeryville, CA USA Med Univ S Carolina, Charleston, SC 29425 USA Med Univ S Carolina Charleston SC USA 29425 ina, Charleston, SC 29425 USA Dana Farber Canc Inst, Boston, MA 02115 USA Dana Farber Canc Inst Boston MA USA 02115 Canc Inst, Boston, MA 02115 USA
Titolo Testata:
LUNG CANCER
fascicolo: 3, volume: 32, anno: 2001,
pagine: 227 - 236
SICI:
0169-5002(200106)32:3<227:PCOOSF>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
DIAGNOSIS; SURVIVAL; PROJECT; STAGE;
Keywords:
cost-effectiveness analysis; lung cancer screening; helical computed-tomography; Early Lung Cancer Action Project;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Marshall, D McMaster Univ, St Josephs Hosp, Ctr Evaluat Med, 50 Charlton Ave,E H-304, Hamilton, ON L8N 4A6, Canada McMaster Univ 50 Charlton Ave,E H-304 Hamilton ON Canada L8N 4A6
Citazione:
D. Marshall et al., "Potential cost-effectiveness of one-time screening for lung cancer (LC) ina high risk cohort", LUNG CANC, 32(3), 2001, pp. 227-236

Abstract

The development of low-dose helical computed-tomography (CT) scanning to detect nodules as small as a few mm has sparked renewed interest in lung cancer (LC) screening. The objective of this study was to assess the potentialhealth effects and cost-effectiveness of a one-time low-dose helical CT scan to screen for LC. We created a decision analysis model using baseline results from the Early Lung Cancer Action Project (ELCAP); Surveillance, Epidemiology and End Results (SEER) registry public-use database: screening program costs estimated from 1999 Medicare reimbursement rates: and annual costs of managing cancer and non-cancer patients from Riley et al. (1995) [MedCare 1995:33(8):828-841] and Taplin et al. (1995) [J Nail Cancer Inst 1995:87(6):417-26], The main outcome measures included years of life, cost estimates of baseline diagnostic screening and Follow up, and cost-effectiveness of screening. We found that in a very high-risk cohort (LC prevalence of 2.7%) of patients between 60 and 74 years of age. a one-time screen appearsto be cost-effective at $5940 per life year saved. In a lower risk generalpopulation of smokers (LC prevalence of 0.7%), a one-time screen appears to be cost-effective at $23 100 per life year. Even when a lead-time bias of1 year is incorporated into the model for a low risk population, the cost-effectiveness is estimated at $58 183 per life year. Based on the assumptions embedded in this model, one-time screening of elderly high-risk patientsfor LC appears to be cost-effective. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/21 alle ore 03:44:10